A Second Look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with a bariatric medicine specialist.Ticker(s): VKTX
Institution: University of Utah Medical Center
- Director of the Obesity Medicine Program and Co-Director of the Comprehensive Weight Management Program at the University of Utah.
- Treats 200 patients a month with obesity (100 with Type 2 Diabetes).
- Research and clinical interests in medical weight management, genetics of obesity, and chronic disease management.
Does a dual GLP-1/GIP Receptor Agonist have a clear benefit to you over semaglutide?
What are your thoughts and key take aways from the Phase 1 trial of VK2735?Added By: sara_admin
Please discuss if there are additional beneficial synergistic merits above and beyond the activity of each individual component.Added By: sara_admin
Do you think Viking Therapeutics plans to make an oral version of VK2735 is feasible?Added By: sara_admin
How would you rate your level of excitement for VK2735 on a scale from 1-10?(10 being the most excited)Added By: sara_admin
Is insurance coverage a big factor in starting patients on a dual GLP-1/GIP Receptor Agonist?Added By: sara_admin
How do you see the side effect profile? Would there be a differentially higher tolerance of side effects in diabetic patients vs. obese patients. Do you view a lower side effect profile (as suggested by the 2735 P1 data) as a major factor for patient compliance in the diabetic and/or obese patient population?Added By: sara_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.